Circadian misalignment is emerging as a significant, under-discussed side effect of GLP-1 receptor agonists. As Medicare expands access to semaglutide and tirzepatide for weight management, millions more will experience the metabolic benefits of these drugs. Yet the sleep disruption they can cause, fragmented architecture, delayed sleep onset, reduced slow-wave sleep, is not trivial. The St. Petersburg school of bioregulation has studied a tetrapeptide called Epitalon (Ala-Glu-Asp-Gly) for decades, focusing on its capacity to resynchronize circadian rhythms by acting on the pineal gland and the suprachiasmatic nucleus. This article examines what that body of work tells us about protecting sleep when GLP-1 therapy disturbs the clock. It does not recommend personal use. It simply presents the research record.
Why Circadian Integrity Matters During GLP-1 Therapy
GLP-1 receptor agonists delay gastric emptying and alter glucose fluxes in ways that shift peripheral clocks. A 2023 review in Frontiers in Endocrinology noted that meal timing itself is a potent zeitgeber, and when GLP-1 drugs change appetite rhythms, the master clock in the suprachiasmatic nucleus can desynchronize from feeding-fasting cycles. The result is not just poor sleep. Circadian disruption worsens insulin sensitivity, increases cortisol, and blunts the very metabolic improvements these drugs are meant to deliver. In older adults, who are the primary Medicare population, circadian robustness already declines with age. Pineal melatonin output drops, and sleep becomes more fragmented. Adding a GLP-1 agonist can amplify that fragility. The St. Petersburg group has long argued that peptide bioregulators can restore pineal function, not by supplying exogenous melatonin, but by upregulating the organ's own synthetic machinery. Epitalon is the most studied of these compounds.
The St. Petersburg Bioregulator School
The research tradition at the St. Petersburg Institute of Bioregulation and Gerontology, led for decades by Vladimir Khavinson, operates on a principle distinct from Western pharmacology. Instead of blocking or agonizing a single receptor, short peptides like Epitalon are thought to interact with DNA promoter regions, modulating gene expression in a tissue-specific manner. In a 2003 paper in Neuroendocrinology Letters, Khavinson and colleagues showed that Epitalon increased melatonin production in pineal cell cultures from old rats, restoring levels to those seen in young animals. The peptide also upregulated expression of Clock and Per1 genes in the suprachiasmatic nucleus. This is not a hypnotic. It is a chronobiotic, a compound that reinforces the endogenous circadian machinery. The school has published over 100 studies on Epitalon, many in Russian-language journals, but a growing number in English. Their work on sleep architecture during metabolic stress is directly relevant to the GLP-1 era.
Epitalon Restores Pineal Melatonin Rhythm in Aging Models
In a 2019 study published in Advances in Gerontology, Epitalon was administered to 18-month-old rats for 10 days. Nighttime melatonin peaks, which had flattened with age, were restored to near-young levels. More importantly, the circadian amplitude of melatonin secretion, the difference between day and night, was significantly increased. This matters because GLP-1 drugs can blunt melatonin amplitude indirectly. Late-night eating, common when appetite returns after the drug's peak effect, exposes the pineal to insulin and glucose spikes that suppress melatonin synthesis. Epitalon's mechanism, upregulating arylalkylamine N-acetyltransferase, the key enzyme in melatonin production, could theoretically counteract that suppression. The peptide also increased the density of melatonin receptors in the suprachiasmatic nucleus, improving the brain's ability to read the pineal signal. This dual action, boosting both the hormone and its receptor, is unusual and may explain why the effects persist after the peptide is cleared.
Sleep Architecture Under Metabolic Load: The Epitalon Data
A 2022 review by Khavinson's group in Biogerontology summarized EEG findings from several rodent studies. Epitalon increased total sleep time and, critically, the proportion of slow-wave sleep during the inactive phase. This is the deep, restorative sleep that GLP-1 drugs can reduce. In one experiment, rats given a high-fat diet to model metabolic syndrome showed fragmented sleep with frequent arousals. Epitalon treatment consolidated sleep and lengthened slow-wave episodes. The peptide did not act as a sedative. It simply reinforced the normal circadian drive for sleep at the appropriate time. For a patient on semaglutide who finds themselves wide awake at 3 a.m., this distinction is important. A hypnotic would force sleep but might not restore its quality. A chronobiotic aims to realign the sleep-wake cycle so that sleep occurs naturally. The St. Petersburg data suggest Epitalon can do this even under metabolic stress.
Connection to Western Circadian Science
Western chronobiology has focused on light exposure, melatonin supplements, and timed feeding to manage circadian disruption. The discovery of REV-ERB and ROR nuclear receptors has opened pharmacological avenues, but no approved drug directly targets the core clock. Epitalon's reported effects on Clock and Bmal1 expression place it conceptually near these nuclear receptor pathways. A 2021 paper in Molecules by researchers unaffiliated with the St. Petersburg group confirmed that Epitalon can activate the CLOCK promoter in luciferase reporter assays. This independent replication is noteworthy because the bioregulator school's work has sometimes been met with skepticism. The mechanism appears to involve epigenetic changes, reduced methylation of clock gene promoters, that allow sustained transcription. If GLP-1 drugs disrupt circadian rhythms partly by altering feeding-regulated clock gene expression in peripheral tissues, then a peptide that maintains Clock and Bmal1 transcription could be protective. This is not proven in humans, but the mechanistic overlap is plausible.
Open Questions and the Medicare Context
The most pressing open question is whether Epitalon's circadian effects translate to humans on GLP-1 therapy. The St. Petersburg group has conducted small human trials, mostly in elderly populations, showing improved sleep quality and melatonin rhythms. But none have specifically enrolled patients taking GLP-1 agonists. Another question concerns timing. In animal studies, Epitalon is given in the morning, and its effects on nighttime melatonin require several days to manifest. This suggests a genomic mechanism that resets the clock gradually. For someone starting semaglutide, prophylactic use of a chronobiotic might prevent sleep disruption rather than treat it after it occurs. Except, and this matters, Medicare's expansion of GLP-1 access will bring these drugs to millions who already have age-related circadian decline. The combination could create a large population with treatment-emergent sleep disorders. Research on chronobiotic peptides like Epitalon, Selank, and DSIP deserves attention, not as alternatives to GLP-1 drugs, but as tools to manage their unintended effects on the clock. Epitalon's role in mitigating GLP-1-related sleep fragmentation is an area where the St. Petersburg data are most compelling. Meanwhile, Selank's effects on restorative sleep under GLP-1 offer another angle on the same problem, though Selank acts more on anxiety-driven insomnia than on core clock mechanisms. The bioregulator approach is not about replacing one peptide with another. It is about understanding the regulatory networks that GLP-1 drugs perturb and using short peptides to nudge them back toward homeostasis. Whether this can be done safely and effectively in a Medicare population remains to be studied.
Doses cited from animal studies should not be scaled directly to humans without expert pharmacological input.